Profile: Achillion Pharmaceuticals Inc (ACHN.O)
26 May 2017
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial.
The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program. It has completed three Phase IIa clinical trials with odalasvir, including the -007 trial with sovaprevir, the -005 study, which examined the use of odalasvir with ribavirin alone, and the Proxy Doublet study which examined the use of odalasvir in combination with sofosbuvir. ACH-3422 has demonstrated potency and was well-tolerated in a Phase Ib proof of concept study. It has completed a Phase II clinical trial that evaluated 12 weeks of treatment consisting of sovaprevir and its nonstructural protein 5A (NS5A) inhibitor, odalasvir, with ribavirin for the treatment of genotype 1 HCV (the -007 trial).
The Company has developed tools that enable to manage its compounds and advance its programs. Achillion Automated Chemistry Platform (AACP) is a software that facilitates synthesis of thousands of small molecules in parallel by automating several cumbersome steps involved. Compound Acquisition and Repository Tracking (CART) streamlines scientists' ability to select and acquire compounds for lead identification and optimization. CHEM-ACH is a data mining software that allows analysis of its compounds and their biological activities. Competitive Intelligence & Data Mining (CIDM) is a Web application that analyzes publicly available information to display competitive information, including clinical and preclinical development activities, intellectual property and scientific literature. ComplementWiki is an in-house database of ongoing and completed complement related drug development and clinical trial designs and results. HCVWiki is an in-house database of ongoing and completed HCV therapy clinical trial designs and results. Preclinical Study Tracking System (PSTS) is a Web interface, which is used for accessing the details of its preclinical studies.
The Company competes with Alexion Pharmaceuticals, Inc., Akari Therapeutics, PLC, Alnylam Pharmaceuticals, Inc., Amyndas Pharmaceuticals, S.A., Apellis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., ChemoCentryx, Inc., Genentech, Inc., Omeros Corporation, Ra Pharmaceuticals, Inc., True North Therapeutics, Inc., Merck & Co., Inc., Enanta Pharmaceuticals, Inc., AbbVie Inc., Gilead Sciences, Inc., Regulus Therapeutics Inc. and Novartis AG.
Achillion Pharmaceuticals Inc
300 George St
NEW HAVEN CT 06511-6624
Company Web Links
- BRIEF-Achillion Q1 loss per share $0.15
- BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471
- BRIEF-Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy
- BRIEF-Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million
- BRIEF-Achillion Pharmaceuticals Q4 revenue $15 million